PDF herunterladen
Hamostaseologie 1988; 08(01): 34-46
DOI: 10.1055/s-0038-1659946
Originalarbeiten
Schattauer GmbH

Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten

W. Schneider
1   Medizinische Klinik und Poliklinik, Universität Düsseldorf
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Juni 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • Literatur

  • 1 Ambrus J.L, Ambrus C.M. Blood coagulation in neoplastic disease. In: Onkohämo-staseologie. Gastpar H. (ed) Stuttgart: Schattauer; 1976: 167-173.
    Google Scholar
  • 2 Barrett O.J. The peripheral blood in malignancy. General Practice 1970; 2: 95-100.
    PubMedGoogle Scholar
  • 3 Berger H, Freudenberg N. Todesursachen bei Malignompatienten. Med Welt 1983; 34: 112-118.
    PubMedGoogle Scholar
  • 4 Bessler H, Notti I, Djaldetti M. The effect of partial splenectomy on platelet production in mice. Thromb Haemostas (Stuttgart) 1981; 46: 602-603.
    PubMedGoogle Scholar
  • 5 Bick R.L. Alterations of hemostasis in malignancy. In: Disorders of Hemostasis and Thrombosis. Bick R.L. (ed) Principles of Clinical Practice. New York: Thieme Ine; 1985: 262-287.
    Google Scholar
  • 6 Billroth S. Lectures on surgical pathology and therapeutics. Translated from the 8th ed. London: New Sydenham Society; 1878
    Google Scholar
  • 7 Bizzozero J. Über einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Vir-chows Arch path Anat Physiol klin Med 1982; 90: 261-332.
    PubMedGoogle Scholar
  • 8 Boxer M.A, Braun J, Ellman L. Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg 1978; 113: 808-9.
    CrossrefPubMedGoogle Scholar
  • 9 Burstein S.A, Erb S.K, Adamson J.W, Harker L.A. Immunologie stimulation of early murine hematopoiesis and its abrogation by cyclosporin A. Blood 1982; 59: 851-856.
    PubMedGoogle Scholar
  • 10 Burstein S.A. Interleukin 3 promotes maturation of murine megakaryocytes in vitro. Blood Cells 1986; 11: 469-479.
    PubMedGoogle Scholar
  • 11 Cavender D.E, Haskard D.O, Joseph B, Ziff M. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 1986; 136: 203-207.
    PubMedGoogle Scholar
  • 12 Cheng K, Kummer H. Thrombozytose bei Bronchuskarzinom. Schweiz Med Wo-chenschr 1970; 100: 2003.
    PubMedGoogle Scholar
  • 13 Cline M.J. Monocytes and macrophages: functions and diseases. Ann Intern Med 1978; 88: 78-88.
    CrossrefPubMedGoogle Scholar
  • 14 Cooper E.H, Stone J. Acute phase reactant proteins in cancer. Adv Cane Res 1979; 30: 1-44.
    PubMedGoogle Scholar
  • 15 Crabtree G.R. The molecular biology of fibrinogen. In: The Molecular Basis of Blood Diseases. Stamatoyannopoulos G, Nienhuis A.W, Leder Ph, Majerus P.h.W. (eds) Philadelphia: Saunders Comp; 1987: 631-61.
    Google Scholar
  • 16 Crowther D, Bateman C.J.T. Malignant disease. Clin Haematol 1972; 1: 447-473.
    PubMedGoogle Scholar
  • 17 Davis W.M, Mendez Ross A.O. Thrombocytosis and thrombocythemia: The laboratory and clinical significance of an elevated platelet count. Am J Clin Path 1973; 59: 243-247.
    CrossrefPubMedGoogle Scholar
  • 18 Diehl W.L, Mandelbaum I. The significance of thrombocytosis in patients with carcinoma of the lung. Surg Gynec Obstet 1983; 156: 187-188.
    PubMedGoogle Scholar
  • 19 Dinarello C.A. Interleukin-1 and the pathogenesis of the acute phase response. New Engl J Med 1984; 311: 1413-1418.
    CrossrefPubMedGoogle Scholar
  • 20 Donati M.B, Poggi A, Semeraro N. Coagulation and malignancy. In: Recent Advances in Blood Coagulation 3. Poller L. (ed) Edinburgh, London, Melbourne, New York: Churchill Livingstone; 1981: 227-259.
    Google Scholar
  • 21 Ernst E. Leukozytenzahl - ein Risikoindikator kardiovaskulärer Erkrankungen?. Herz/Kreisl 1987; 19: 108-112.
    PubMedGoogle Scholar
  • 22 Geissler D, Konwalinka G, Peschel C, Grünewald K, Odavic R, Braunsteiner H. A regulatory role of activated T-lymphocytes on human megakaryocytopoiesis in vitro. Brit J Haematol 1985; 60: 233-238.
    CrossrefPubMedGoogle Scholar
  • 23 Geissler K, Korninger C, Niessner H, Lechner K. Verbrauchskoagulopathie bei malignen Tumoren. Blut 1983; 47: 179 (Abstract)
    PubMedGoogle Scholar
  • 24 Gunzenbach R, Grimm J, Trachsler M, Rhyner K. Häufigkeit und klinische Relevanz von Thrombozytosen. Schweiz Med Wochenschr 1982; 112: 38-41.
    PubMedGoogle Scholar
  • 25 Gordon S.G. Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen. Hämostaseologie 1985; 5: 160-165.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 26 Gordon D.H, Schaffner D, Bennett J.M, Schwartz S.I. Postsplenectomy thrombocytosis. Its association with mesenteric, portal, and/or renal vein thrombosis in patients with myeloproliferative disorders. Arch Surg 1978; 113: 713-715.
    CrossrefPubMedGoogle Scholar
  • 27 Greenberger J.S, Krensky A.M, Messner H, Burakoff S.J, Wandl U, Sakakeeny M.A. Production of colony-stimulating factor(s) for granulocyte macrophage and multipo-tential (granulocyte/erythroid/megakaryo-cyte/macrophage) hematopoietic progenitor cells (CFU-GEMM) by clonal lines of human IL-2-dependent T-lymphocytes. Exp Hematol 1984; 12: 720-722.
    PubMedGoogle Scholar
  • 28 Grimm R.H, Neaton J.D, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985; 254: 1932-1937.
    CrossrefPubMedGoogle Scholar
  • 29 Hagedorn A.B, Bowie E.J.W, Elveback L.R, Owen C.A. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1974; 49: 649-653.
    PubMedGoogle Scholar
  • 30 Harker L.A, Finch C.A. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974.
    CrossrefPubMedGoogle Scholar
  • 31 Helbig W. Zur Wertigkeit paraneoplastischer Knochenmark- und Blutbildbefunde. Verh Dtsch Ges Inn Med 1980; 86: 428-432.
    PubMedGoogle Scholar
  • 32 Hirsh J. Hypercoagulability. Sem Hematol 1977; 14: 409-425.
    PubMedGoogle Scholar
  • 33 Ho W.G, Winston D.J. Transfusions and supportive care. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 239-247.
    Google Scholar
  • 34 Kanz L, Lohr G.W, Fauser A.A. Human megakaryocytic progenitor cells. Klin Wochenschr 1987; 65: 297-307.
    CrossrefPubMedGoogle Scholar
  • 35 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636-641.
    CrossrefPubMedGoogle Scholar
  • 36 Kessler C.M, Klein H.G, Havlik R.J. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Brit J Haematol 1982; 50: 157-167.
    CrossrefPubMedGoogle Scholar
  • 37 Koeffler H Ph, Amatruda Th T. Preleukemia. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 197-212.
    Google Scholar
  • 38 Korninger C, Deutsch E. The role of hae-mostasis in malignancy. In: The Cancer Patient. Cancer Campaign, vol 9. Beck L, Grundmann E, Schneider W. (eds) Stuttgart, New York: Fischer; 1985: 79-84.
    Google Scholar
  • 39 Kostis J.B, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography. Am J Cardiol 1984; 53: 997-999.
    CrossrefPubMedGoogle Scholar
  • 40 Levin J, Conley C.D. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114: 497-500.
    CrossrefPubMedGoogle Scholar
  • 41 Lovett D, Kozan B, Hadam M, Resch K, Gemsa D. Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol 1986; 136: 340-347.
    PubMedGoogle Scholar
  • 42 Marx R. Wichtige klinisch-hämostaseologi-sche Phänomene bei Malignomen. In: On-kohämostaseologie. Gastpar H. (ed) Stuttgart, New York: Schattauer; 1976: 3-20.
    Google Scholar
  • 43 Mason J.E, De Vita V.T, Canellos G.P. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974; 44: 483-487.
    PubMedGoogle Scholar
  • 44 Mayr A.C, Dick H.J, Nagel G.A, Senn H.J. Thrombozytose bei malignen Tumoren. Schweiz Med Wochenschr 1973; 103: 1626-1629.
    PubMedGoogle Scholar
  • 45 Minar E, Ehringer H, Marosi L, Hiischi M, Konecny U, Pollak Ch, Czembirek H, Sommer G. Akute Venenthrombose. Lokalisation, Ausdehnung und Ätiologie mit besonderer Berücksichtigung der Paraneoplasie. Dtsch Med Wochenschr 1982; 107: 1303-1309.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 46 Monick M, Glazier J, Hunninghake G.W. Human alveolar macrophages suppress in-terleukin-1 (IL-1) activity via the secretion of prostaglandin E2 . Am Rev Respir Dis 1987; 135: 72-77.
    PubMedGoogle Scholar
  • 47 Morley A.A, Baikie A.G, Galton D.A.G. Cyclic leucocytosis as evidence for retention of normal homoeostatic control in chronic granulocytic leukaemia. Lancet 1967; II: 1320-1323.
    PubMedGoogle Scholar
  • 48 Morowitz D.A, Allen L.W, Kirsner J.B. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968; 68: 1013-1021.
    CrossrefPubMedGoogle Scholar
  • 49 Mosher D.F. Fibronectin. Progr Hemost Thrombos 1980; 5: 111-151.
    PubMedGoogle Scholar
  • 50 Munzarova M, Kovarik J. Ist Krebs eine makrophagenvermittelte Autoimmunerkrankung?. The Lancet (deutsche Ausgabe) 1987; 1: 571-574.
    PubMedGoogle Scholar
  • 51 Murphy S. Thrombocytosis and thrombo-cythaemia. Clin Haematol 1983; 12: 89-106.
    PubMedGoogle Scholar
  • 52 Nakano T, Fujii J, Tamura S, Hada T, Hagashino K. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer 1986; 58: 1699-1701.
    CrossrefPubMedGoogle Scholar
  • 53 O’Neill B. Monocytosis in malignant disease. Ann Intern Med 1970; 73: 991-992.
    CrossrefPubMedGoogle Scholar
  • 54 Odell W.D, Wolfsen A.R. Humoral syndromes associated with cancer. Ann Rev Med 1978; 29: 379-406.
    CrossrefPubMedGoogle Scholar
  • 55 Ouesenberry P.J, Ihle J.N, McGrath E. The effect of interleukin 3 and GM-CSA-2 on megakaryocyte and myeloid clonal colony formation. Blood 1985; 65: 214-217.
    PubMedGoogle Scholar
  • 56 Rabellino E.M, Levene R.B, Nachman R.L, Leung L. Human megakaryocytes III. Characterization in myeloproliferative disorders. Blood 1984; 63: 615-622.
    PubMedGoogle Scholar
  • 57 Rasche H. Hämostasedefekte durch Umsatzstörungen bei soliden Tumoren und malignen hämatologischen Systemerkrankungen. In: Handbuch der Inneren Medizin, Bd. 2, Teil 9:Blutgerinnung und hämorrhagische Diathesen II. Heene D.L. (Hrsg) Berlin, Heidelberg, New York: Springer.; 1985: 650-674.
    Google Scholar
  • 58 Rickles F.R, Edwards R.L. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
    PubMedGoogle Scholar
  • 59 Riess L. Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 1872; 237-249.
    PubMedGoogle Scholar
  • 60 Robbins G, Barnard D.L. Thrombocytosis and Microthrombocytosis : A clinical evaluation of 372 cases. Acta Haematol 1983; 70: 175-182.
    CrossrefPubMedGoogle Scholar
  • 61 Ruff M.R, Pert C.B. Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. Science 1984; 225: 1034-1036.
    CrossrefPubMedGoogle Scholar
  • 62 Sack G.H, Levin J, Bell W.R. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 1-37.
    CrossrefPubMedGoogle Scholar
  • 63 Schafer A.I. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12.
    PubMedGoogle Scholar
  • 64 Scharf R.E, Theis O, Schneider W. Plättchensekretion und Thrombinaktivität bei Malignompatienten . Hämostaseologie 1985; 5: 166-169.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Schneider W. Unveröffentlichte Befunde.
    PubMed
  • 66 Schneider W. Küche O. 2-h-Wert der Blutkörperchensenkung. Intern Praxis 1987; 27: 453-454.
    PubMedGoogle Scholar
  • 67 Schneider W, Morgenstern E. Zellbiologische Grundlagen der Plättchenfunktion. In: Praktische Anwendung der Thrombozyten -funktionsdiagnostik. von Voss H, Göbel U. (Hrsg) Stuttgart: Thieme; 1980: 1-16.
    Google Scholar
  • 68 Schneider W, Scharf R.E, Hagen-Aukamp Ch, Winkelmann M. Evolution der Hämostase : Megakaryozyten-Blutplättchen-Sy-stem. Arzneim-Forsch/Drug Res 1983; 33 (11) 1351-1354.
    PubMedGoogle Scholar
  • 69 Schneider W, Winkelmann M. Hematological tumor signs. In: The Cancer Patient. Cancer Campaign, vol 9. Beck L, Grundmann E, Schneider W. (eds) Stuttgart, New York: Fischer; 1985: 71-77.
    Google Scholar
  • 70 Schwartz C.J, Valente A.J, Sprague E.A, Kelly J.L, Suenram C.A, Graves D.T, Rozek M.M, Edwards E.H, Delgado R. Monocyte-makrophage participation in atherogenesis : inflammatory components of pathogenesis. Semin Thromb Hemostas 1986; 12: 79-86.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 71 Selroos O. Thrombocytosis. Acta Med Scand 1973; 193: 431-436.
    PubMedGoogle Scholar
  • 72 Silvis S.E, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA 1970; 211: 1852-1853.
    CrossrefPubMedGoogle Scholar
  • 73 Silvis S.E, Turkbas N, Swaim W.R, Doscherholmen A. Thrombocytosis. A clinical evaluation of 322 patients. Minn Med 1969; 52: 1603-1607.
    PubMedGoogle Scholar
  • 74 Slichter S.J, Harker L.A. Hemostasis and malignancy. Ann NY Acad Sci 1974; 230: 252-261.
    CrossrefPubMedGoogle Scholar
  • 75 Snipper L.E. Clinical implications of tumor cell heterogeneity. New Engl J Med 1986; 314: 1423-1431.
    CrossrefPubMedGoogle Scholar
  • 76 Spigel S.C, Mooney L.R. Extreme thrombocytosis associated with malignancy. Cancer 1977; 39: 339-341.
    CrossrefPubMedGoogle Scholar
  • 77 Stossel Th P. The molecular biology of phagocytes and the molecular basis of nonneoplastic phagocyte disorders. In: The Molecular Basis of Blood Diseases. Stama-toyannopoulos G, Nienhuis A.W, Leder Ph, Majerus P.h.W. (eds) Philadelphia: Saunders Comp; 1987: 499-533.
    Google Scholar
  • 78 Sun N.C, McAfee W.M, Hum G.J, Weiner J.M. Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979; 71: 10-16.
    CrossrefPubMedGoogle Scholar
  • 79 Thaler E, Niessner H, Lechner K. Chronische Verbrauchskoagulopathie bei Carcinom. In: Onkohämostaseologie. Gastpar H. (Hrsg) Stuttgart: Schattauer; 1976: 201-204.
    Google Scholar
  • 80 Thompson R.B, Stainsby D. The clinical and haematoiogical features of chronic granulocytic leukaemia in the chronic phase. In: Chronic Granulocytic Leukaemia. Shaw M.T. (ed) Eastbourne, New York : Praeger Publishers; 1982: 137-167.
    Google Scholar
  • 81 Tranum B.L, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974; 84: 615-619.
    PubMedGoogle Scholar
  • 82 Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de L’Hotel-Dieu de Paris. Balliere 1865; 3: 654-656.
    PubMedGoogle Scholar
  • 83 Wegmann D. Paraneoplastische Thrombose - eine mortalitätsstatistische Untersuchung. Vasa 1981; 10: 111-118.
    PubMedGoogle Scholar
  • 84 Wehmeier A, Scharf R.E, Schneider W. Thrombose und Blutungsneigung bei myeloproliferativen Erkrankungen. Hämostaseologie 1985; 5: 185-192.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 85 Wilmanns W, Possinger K. Paraneoplastische Syndrome - eine Hilfe bei der Früherkennung maligner Tumoren ?. Verh Dtsch Ges Inn Med 1986; 92: 66-76.
    PubMedGoogle Scholar
  • 86 Winkelmann M. DNA-Gehalt und Reifegrad der Megakaryozyten bei Erkrankungen mit Hämostasestörungen. Habilitationsschrift, Düsseldorf 1987.
    PubMedGoogle Scholar
  • 87 Winkelmann M, Pfitzer P, Schneider W. Polyploidy of cells and tissues in relation to the ploidy of megakaryocytes. Klin Wochenschr (im Druck).
    PubMedGoogle Scholar
  • 88 Winkelmann M, Stöckler J, Grasmuck J, Pfitzer P, Schneider W. Ploidy pattern of megakaryocytes in patients with metastatic tumors with and without paraneoplastic thrombosis and in controls. Haemostasis 1984; 14: 501-507.
    PubMedGoogle Scholar
  • 89 Winston D.J, Ho W.G, Gale R.P, Champlin R.E. Prevention and treatment of infection in leukemia patients. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 213-238.
    Google Scholar
  • 90 Zacharski L.R. Biologische Grundlagen einer Antikoagulantienbehandlung bei Tumorkrankheiten. Hämostaseologie 1985; 5: 178-184.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 91 Zöllner N. Der leise Beginn chronischer Krankheiten - Beiträge zu ihrer Frühsymptomatologie und zur Nosologie der Frühstadien - Einführung. Verh Dtsch Ges Inn Med 1986; 92: 1-2.
    PubMedGoogle Scholar